Iovance Biotherapeutics Inc. Common Stock vs NOV Inc. Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while NOV Inc. Common Stock trades at $18.97 (market cap $6.77B). The key difference: Iovance Biotherapeutics Inc. Common Stock and NOV Inc. Common Stock are close in size by market cap, and NOV Inc. Common Stock pays a 1.9% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and NOV Inc. Common Stock for 1 Days on average.
| IOVA | NOV | |
|---|---|---|
Market Cap | $6.04B | $6.77B |
Volume | 14,805,993 | 3,592,724 |
Sector | Health | Energy |
52-Week High | $14.82 | $21.71 |
52-Week Low | $1.81 | $12.31 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $5.97B | $7.93B |
Dividend Yield | — | 1.9% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →NOV provides technology, equipment, and services for energy production. Its offerings support drilling, well construction, and production across oil, gas, renewables, and emerging energy markets.
Read more on NOV →